IGF-1 LR3 complete guide

Insulin-like Growth Factor 1 (IGF-1) is the major mediator of growth-hormone’s anabolic effects — a 70-amino-acid peptide structurally related to insulin (hence the name) and produced primarily by hepatocytes in response to pituitary GH stimulation. IGF-1 LR3 (“Long R3”) is a modified IGF-1 analog with two deliberate structural changes: (1) an N-terminal 13-amino-acid extension — the “Long” part — and (2) substitution of glutamic acid at position 3 with arginine — the “R3” part. These modifications reduce binding affinity to the IGF binding proteins (IGFBPs), particularly IGFBP-3, by approximately 100-fold. The pharmacokinetic consequence is that more free, bioavailable IGF-1 LR3 reaches the IGF-1 receptor in research models, and plasma half-life extends from native IGF-1's ~10-15 minutes to LR3's ~20-30 hours.

Within the GH/IGF-1 axis research toolkit, IGF-1 LR3 occupies a mechanistically distinct position from GHRH-class compounds. Sermorelin, Tesamorelin and CJC-1295 act upstream on pituitary GHRH receptors and rely on the intact pituitary-liver-IGF-1 cascade to produce their downstream effects. IGF-1 LR3 acts directly at the final step — the IGF-1 receptor in target tissues — bypassing the pituitary and liver entirely. This makes IGF-1 LR3 the most-studied IGF-1 analog in published anabolic-research literature, and the canonical tool when research designs need to isolate IGF-1-mediated effects from upstream GH-pulse dynamics.

Quick reference — IGF-1 LR3 identifiers

Property	IGF-1 LR3
Class	Modified Insulin-like Growth Factor 1 analog (“Long R3” variant)
Synonyms	Long R3 IGF-1, LR3 IGF-1, IGF-1 Long-R3
Sequence	83 amino acids: 13-aa N-terminal extension + 70-aa IGF-1 with E3R substitution
Receptor target	IGF-1 receptor (IGF1R) — receptor tyrosine kinase, α2β2 tetrameric structure
Molecular formula	~C400H625N111O115S9 (approximate)
Molecular weight	~9111 g/mol
CAS number	946870-92-4
Origin	Recombinant E. coli expression of modified IGF-1
Plasma half-life (research models)	~20-30 hours (vs native IGF-1 ~10-15 min)
IGFBP-3 binding affinity	~100× reduced vs native IGF-1
Vial strengths (TogoPeptide)	1 mg lyophilized (small dose, high potency)

Origin and structure — engineered for IGFBP independence

Native IGF-1 is a 70-residue single-chain peptide with three disulfide bonds, structurally homologous to insulin and proinsulin. It is produced primarily by the liver in response to pituitary GH stimulation, and circulates almost entirely (~99%) bound to a family of six IGF binding proteins (IGFBPs 1-6). IGFBP-3 is the dominant carrier in plasma and forms a ternary complex with IGF-1 and an acid-labile subunit (ALS). The bound fraction is biologically inactive and acts as a circulating reservoir; only the very small free fraction of IGF-1 binds the IGF-1 receptor and activates downstream signaling.

IGF-1 LR3 was engineered specifically to disrupt this dynamic. Two structural modifications combine: the 13-amino-acid N-terminal extension (originally derived from a methionyl-arginyl extension intended for recombinant expression) and the substitution of glutamic acid at position 3 with arginine. Together, these changes prevent normal IGFBP binding while leaving the IGF-1-receptor-binding interface essentially unchanged. The result is an analog that retains full agonism at the IGF-1 receptor but distributes very differently in plasma — more free peptide reaching receptor, and a longer effective half-life because the peptide is no longer trapped in the IGFBP/ALS reservoir.

Frame this as elegant medicinal chemistry: same receptor pharmacology as native IGF-1, modified pharmacokinetics. The receptor binds the same IGF-1 face it always did; the IGFBPs no longer recognize the modified N-terminus; and the consequence is a longer, freer, and (by some research metrics) more potent molecule.

Mechanism — IGF-1 receptor agonism

IGF-1 receptor (IGF1R) binding

IGF-1 LR3 retains full binding affinity for the IGF-1 receptor (IGF1R), a tetrameric receptor tyrosine kinase with an α₂β₂ structure closely related to the insulin receptor (IR). The two receptors share approximately 60% sequence homology in the extracellular ligand-binding domains and ~85% in the intracellular tyrosine-kinase domains, and they can form hybrid IR/IGF1R receptors in cells expressing both. Agonist binding to the α-subunits triggers transphosphorylation of the β-subunit kinase domains and recruitment of insulin-receptor-substrate (IRS) family adaptor proteins. Published research consistently documents IGF-1 LR3 IGF1R activation across research-cell-line and research-animal models.

PI3K-Akt-mTOR pathway activation

The dominant downstream pathway from IGF1R is the PI3K-Akt-mTOR axis. Phosphorylated IRS-1/IRS-2 recruits the p85 regulatory subunit of phosphoinositide 3-kinase (PI3K), generating PIP₃ at the plasma membrane and activating Akt (also known as PKB). Akt is the central anabolic node: it activates mTOR complex 1 (mTORC1) to drive protein synthesis via S6K1 and 4E-BP1, it suppresses FoxO transcription factors to inhibit proteolysis (reducing MuRF1 / atrogin-1 expression), and it promotes glucose uptake via GLUT4 trafficking. This is the pathway responsible for IGF-1's classical anabolic phenotype — increased muscle protein synthesis, reduced muscle protein breakdown, and increased glucose disposal in research models.

MAPK pathway and cellular proliferation

The secondary downstream pathway is the Ras-Raf-MEK-ERK MAPK cascade. IRS-1 also recruits the Grb2/SOS adaptor complex, activating Ras and the downstream ERK1/2 MAPK kinases. ERK1/2 drives transcriptional programs of cellular proliferation and is the basis for the IGF-1 LR3 research literature in tissue-regeneration and developmental research designs. Where the PI3K-Akt arm is the protein-synthesis / hypertrophy arm, the MAPK arm is the proliferation / division arm — the two together account for most of the published IGF-1 LR3 phenotype.

IGFBP independence — pharmacokinetic significance

An important mechanism point: native IGF-1's heavy IGFBP binding means that most administered native IGF-1 enters the bound reservoir rather than reaching the IGF-1 receptor. IGF-1 LR3's reduced IGFBP binding means that proportionally more of the administered peptide reaches receptor — making IGF-1 LR3 approximately 3× more potent than native IGF-1 by some research metrics, despite essentially identical IGF1R binding affinity. The potency difference is therefore a pharmacokinetic property (free-fraction availability, tissue distribution, plasma persistence), not a pharmacodynamic one (receptor signaling intensity). This distinction matters when comparing dose-response curves across the IGF-1 analog series.

Anabolic and protein-synthesis research

The largest published IGF-1 LR3 research line concerns muscle protein synthesis, muscle-cell hypertrophy, and satellite-cell activation in research-animal and cell-culture models. The PI3K-Akt-mTOR pathway is well-characterized in this literature: IGF-1 LR3 administration drives Akt phosphorylation, mTORC1 activation, and downstream phosphorylation of S6K1 and 4E-BP1 — the canonical translational-control nodes for protein synthesis. Parallel suppression of FoxO activity reduces proteolytic-program transcription. Net effect in published research-animal protein-balance studies is a positive shift toward synthesis. IGF-1 LR3 has been particularly used in catabolic research-models (dexamethasone-treated, diabetic, immobilized) to characterize the anti-catabolic side of the IGF1R signaling pathway.

Tissue-regeneration research

Published research-animal-model literature also documents IGF-1 LR3 effects in wound-healing, bone-fracture-healing, and tendon-repair research designs, downstream of the MAPK proliferation pathway and the integrative PI3K-Akt anti-apoptotic effects. IGF1R is broadly expressed across mesenchymal lineages, and IGF-1 has long been characterized in the developmental-biology literature as a major paracrine growth factor coordinating tissue maintenance and repair. IGF-1 LR3's extended plasma persistence makes it a preferred research tool when sustained IGF1R stimulation is needed across the days-to-weeks timescale of a regeneration experiment.

Glucose metabolism research

Published research documents IGF-1 LR3 effects on glucose disposal and insulin sensitivity in research-animal designs, downstream of Akt-mediated GLUT4 trafficking. An important pharmacological note: high-affinity IGF1R activation can also stimulate the closely-related insulin receptor (IR) at higher concentrations, and IGF1R/IR hybrid receptors complicate strict pathway attribution. Glucose-metabolism effects in IGF-1 LR3 research models therefore have multiple potential mechanistic pathways — direct IGF1R signaling, hybrid-receptor signaling, and at high local concentrations cross-reactivity with IR. Published research designs that aim to dissect these pathways typically use receptor-knockout or selective-antagonist approaches.

IGF-1 LR3 vs native IGF-1 vs IGF-1 DES(1-3)

Compound	Modification	Plasma half-life	IGFBP affinity	Receptor potency
Native IGF-1	None	~10-15 min	High (>99% bound)	Reference
IGF-1 LR3	N-term + 13aa, E3R	~20-30 hours	~100× reduced	~3× higher (free fraction)
IGF-1 DES(1-3)	First 3 aa removed	~3-4 hours	Moderately reduced	~10× higher (in some assays)

Three IGF-1 analogs, three different research applications. IGF-1 LR3 is the tool of choice for sustained-elevation studies — its multi-hour half-life supports research designs that need persistent IGF1R signaling. IGF-1 DES(1-3) is preferred for high-receptor-potency studies — by removing the first three residues of native IGF-1, this analog shows reduced IGFBP affinity and high apparent receptor potency in some assays, but with shorter persistence than LR3. Native IGF-1 remains the reference compound for physiology research and any design that needs the natural IGFBP-buffered pharmacokinetics.

Comparison to GHRH-class compounds (CJC-1295, Sermorelin, Tesamorelin)

Within the GH/IGF-1 axis research framework, GHRH-class compounds and IGF-1 LR3 are complementary rather than competitive. GHRH compounds (Sermorelin, Tesamorelin, CJC-1295) work upstream on the pituitary, driving endogenous pulsatile GH release and downstream hepatic IGF-1 production. IGF-1 LR3 works downstream, directly at the target-tissue IGF-1 receptor.

This means published research designs can use the two classes in series to dissect which axis-position contributes to specific outcomes. A research-animal protocol that uses CJC-1295 + Ipamorelin to elevate endogenous GH and IGF-1, plus exogenous IGF-1 LR3 to further saturate IGF1R, can compare the relative contributions of GH-direct effects (mediated by hepatic and peripheral GHR signaling) versus IGF-1-mediated effects (mediated by IGF1R). This kind of axis-dissection design is the canonical way the literature has used the two compound classes together.

Storage and handling

IGF-1 LR3 ships as lyophilized powder. Standard research-handling literature documents:

• Lyophilized state: sealed at −20°C, protected from light. Stable for the manufacturer-stated window under proper storage.
• Diluent: bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution diluent. Some research protocols use weak acid (0.1% acetic acid) for the lyophilization-stage reconstitution, though bacteriostatic water remains the standard for downstream working solutions.
• Reconstituted state: refrigerate at 2–8°C immediately after reconstitution. Research-handling literature for IGF-1 analogs documents an approximate 28-day reconstituted shelf life under refrigeration.
• Avoid freeze-thaw cycles after reconstitution. The disulfide-bonded structure of IGF-1 is sensitive to repeated phase changes; aggregation and disulfide scrambling are the main degradation pathways.
• Small-dose vials require careful reconstitution math. Because IGF-1 LR3 is supplied at 1 mg per vial and is highly potent at microgram-scale research concentrations, careful stock-solution dilution and consistent volumetric handling are critical. See the reconstitution calculator for stock-to-working-solution arithmetic.
• Vial inspection: clear, colorless solution after reconstitution. Cloudiness or particulates indicate aggregation or microbial compromise; discard and re-reconstitute fresh.

Each TogoPeptide IGF-1 LR3 shipment includes a per-batch Certificate of Analysis with HPLC purity (target ≥98%), mass-spectrometry identity confirmation, lot number, manufacture date and analysis date. See how to read a COA or reconstitution methodology for handling-protocol details.

Cross-research lines and pairings

IGF-1 LR3 is most-cited in published research alongside related GH/IGF-1-axis compounds. Common research-design pairings:

• GH-axis full-stack research design — CJC-1295 + Ipamorelin (upstream GH stimulation via parallel GHRH and ghrelin-receptor pathways) plus IGF-1 LR3 (direct IGF-1 receptor activation). The canonical research design when the goal is sustained engagement of the entire GH/IGF-1 axis from pituitary through to peripheral receptor. See the Performance Stack for the curated compound set.
• Tesamorelin pairing — Tesamorelin’s published research line concerns visceral adipose tissue endpoints, and IGF-1 LR3's anabolic-research line concerns lean-tissue endpoints. Co-administration designs allow researchers to study composition-shift dynamics where GH stimulates lipolysis upstream and IGF-1 stimulates lean-tissue protein synthesis downstream.
• Reconstitution-calculator workflow — IGF-1 LR3's small mg-dose vials and high research potency make accurate stock-solution preparation essential. Use the reconstitution calculator for stock-to-working-solution arithmetic, and the reconstitution methodology guide for the underlying principles.
• IGF-1 analog comparison designs — protocols that dose IGF-1 LR3, IGF-1 DES(1-3), and native IGF-1 in parallel arms to characterize IGFBP-independence × half-life × receptor-potency relationships within the IGF-1 analog family.

Closing

IGF-1 LR3's research position is unique within the GH/IGF-1 axis: it is the most-studied IGF-1 analog in the published anabolic-research literature, and the canonical tool for downstream-axis research designs. The N-terminal extension and R3 substitution decouple the molecule from IGFBP regulation while preserving full IGF-1-receptor agonism — a clean medicinal-chemistry strategy that produces an analog distinguishable from native IGF-1 by pharmacokinetics rather than pharmacodynamics. For published research that needs sustained IGF1R signaling independent of the pituitary axis, IGF-1 LR3 remains the foundational tool.

This guide documents what published peer-reviewed research has investigated. It is structural and mechanism context for laboratory researchers, not therapeutic recommendation, not protocol guidance, not a basis for self-administration of any kind.

Source IGF-1 LR3 for laboratory research:

• IGF-1 LR3 product page — full identifiers, 1 mg lyophilized vial, per-batch COA
• Performance Stack — curated GH/IGF-1-axis research bundle (CJC-1295+Ipamorelin blend, Sermorelin, Tesamorelin)
• Performance / GH-axis research compounds — full category listing

For methodology and laboratory-handling questions, contact our research-supply team at info@togopeptide.com.